CINECA IRIS Institutional Research Information System

TERZOLO, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.212
EU - Europa 20.093
AS - Asia 10.801
SA - Sud America 2.324
OC - Oceania 597
AF - Africa 518
Continente sconosciuto - Info sul continente non disponibili 29
Totale 54.574
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.782
IT - Italia 4.390
CN - Cina 3.889
DE - Germania 2.632
FR - Francia 1.733
GB - Regno Unito 1.459
JP - Giappone 1.415
ES - Italia 1.318
IE - Irlanda 1.100
SE - Svezia 1.094
BR - Brasile 1.084
TR - Turchia 984
PL - Polonia 774
CA - Canada 769
NL - Olanda 769
UA - Ucraina 760
SG - Singapore 742
KR - Corea 721
IN - India 682
FI - Finlandia 656
MX - Messico 559
AU - Australia 538
AR - Argentina 479
VN - Vietnam 427
CH - Svizzera 407
AT - Austria 399
GR - Grecia 368
CO - Colombia 325
PT - Portogallo 324
BE - Belgio 320
RU - Federazione Russa 296
IL - Israele 295
HK - Hong Kong 286
RO - Romania 246
TW - Taiwan 241
TH - Thailandia 222
CL - Cile 192
MY - Malesia 172
DK - Danimarca 162
HU - Ungheria 148
DZ - Algeria 143
CZ - Repubblica Ceca 117
PH - Filippine 117
NO - Norvegia 111
PE - Perù 111
RS - Serbia 110
HR - Croazia 107
SA - Arabia Saudita 97
ID - Indonesia 95
IR - Iran 82
EC - Ecuador 75
TN - Tunisia 74
EG - Egitto 68
SI - Slovenia 63
ZA - Sudafrica 59
PK - Pakistan 56
SN - Senegal 56
NZ - Nuova Zelanda 55
IQ - Iraq 48
BG - Bulgaria 46
MA - Marocco 36
SK - Slovacchia (Repubblica Slovacca) 35
VE - Venezuela 32
AE - Emirati Arabi Uniti 31
BA - Bosnia-Erzegovina 29
KE - Kenya 28
BY - Bielorussia 26
OM - Oman 24
EU - Europa 21
LT - Lituania 19
UZ - Uzbekistan 19
BD - Bangladesh 18
LB - Libano 18
PA - Panama 18
SY - Repubblica araba siriana 17
LV - Lettonia 16
MT - Malta 16
CR - Costa Rica 15
CY - Cipro 15
DO - Repubblica Dominicana 14
QA - Qatar 13
UY - Uruguay 13
AM - Armenia 12
JO - Giordania 12
KZ - Kazakistan 12
GT - Guatemala 10
MK - Macedonia 10
BO - Bolivia 9
CU - Cuba 9
KW - Kuwait 9
ME - Montenegro 9
GE - Georgia 8
MU - Mauritius 8
NP - Nepal 8
TZ - Tanzania 8
LK - Sri Lanka 7
LU - Lussemburgo 7
NI - Nicaragua 7
SV - El Salvador 7
UG - Uganda 7
Totale 54.481
Salva come PNG Salva come JPEG
Città #
Beijing 1.876
Chandler 1.736
Fairfield 1.160
Houston 1.072
Dublin 1.037
Redwood City 891
Ashburn 731
Woodbridge 613
Ann Arbor 593
Seattle 556
Wilmington 555
Torino 544
Singapore 513
Cambridge 456
Jacksonville 412
Warsaw 401
Milan 353
Medford 345
Nyköping 343
Villeurbanne 338
Princeton 306
Pisa 288
Vienna 274
Paris 270
Rome 269
Buenos Aires 248
Tokyo 247
Madrid 245
Würzburg 243
New York 235
Istanbul 228
Shanghai 228
Dong Ket 226
Guangzhou 220
Dearborn 215
Rochester 200
Turin 198
Ankara 184
London 171
Boston 169
São Paulo 168
Munich 166
Barcelona 163
Los Angeles 155
Athens 150
Bogotá 148
Santiago 143
Berlin 141
Chicago 140
Fremont 138
Hangzhou 137
Taipei 137
Toronto 136
San Diego 117
Bologna 111
Brescia 111
Bangkok 106
Nanjing 106
Seoul 106
Sydney 106
Budapest 102
Florence 101
Mexico City 97
Moscow 93
Chengdu 91
Montreal 91
Brussels 90
Bethesda 84
Rotterdam 84
Adelaide 83
Zurich 82
Amsterdam 81
Lima 81
Boardman 80
Bucharest 79
Helsinki 78
Birmingham 77
Central 77
Brisbane 76
Porto 72
Pittsburgh 70
Philadelphia 68
Frankfurt am Main 67
Belgrade 66
Oslo 66
Padova 66
Verona 64
Washington 64
Lisbon 61
Leiden 60
Kuala Lumpur 59
Phoenix 58
San Francisco 58
Valencia 57
Delhi 56
Düsseldorf 56
Silver Spring 56
Shenyang 54
Baltimore 52
New Delhi 52
Totale 24.783
Salva come PNG Salva come JPEG
Nome #
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. 10.932
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors 4.646
European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors 1.462
New perspectives for mitotane treatment of adrenocortical carcinoma 1.098
The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases. 1.063
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. 892
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. 779
Practical treatment using mitotane for adrenocortical carcinoma. 742
Hypertension and Acromegaly 695
Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma 664
Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: A systematic review and meta-Analysis 657
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 652
Autonomous hypercortisolism: definition and clinical implications 605
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. 498
Long-term follow-up in adrenal incidentalomas: an Italian Multicenter Study. 472
Management of adrenal cancer: a 2013 update. 446
Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases. 422
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 409
AME position statement on adrenal incidentaloma. 409
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. 406
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 405
Comparison of Two Mitotane Starting dose Regimens in Patients with Advanced Adrenocortical Carcinoma. 394
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. 375
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma 370
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas 366
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE) 353
Combination Chemotherapy in Advanced Adrenocortical Carcinoma. 353
Thyroid and colorectal cancer screening in acromegaly patients: Should it be different from that in the general population? 325
Management of adjuvant mitotane therapy following resection of adrenal cancer. 322
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. 317
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer 313
MITOTANE LEVELS PREDICT THE OUTCOME OF PATIENTS WITH ADRENOCORTICAL CARCINOMA TREATED ADJUVANTLY FOLLOWING RADICAL RESECTION. 309
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 305
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. 303
18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. 302
Merits and pitfalls of mifepristone in Cushing's syndrome 297
Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. 285
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: A multicenter study 276
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. 274
Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas 272
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates 260
Surgical remission of Cushing's syndrome reduces cardiovascular risk. 251
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization 244
Adjuvant mitotane treatment for adrenocortical carcinoma 240
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma 238
Analysis of BCLI, N363S and ER22/23EK polymorphisms of the glucocorticoid receptor gene in adrenal incidentalomas 230
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. 227
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease 224
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 223
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. 214
Abiraterone and increased survival in metastatic prostate cancer. 211
Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal nonosteoporotic women in the early postmenopausal period. 211
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 204
In vitro antitumor activity of progesterone in human adrenocortical carcinoma. 203
Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors 199
Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma 188
Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. 183
Predictors of morbidity and mortality in acromegaly: an Italian survey. 180
Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major 178
Diagnosi e terapia del carcinoma corticosurrenalico 173
Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. 172
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 170
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment. 169
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study 167
Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis. 165
Acromegaly is associated with increased cancer risk: a survey in Italy 160
Determination of salivary cortisol to assess time related changes of the adrenal response to stress in critically ill patients 154
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 153
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. 151
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. 150
24-hour profiles of blood pressure and heart rate in Cushing's syndrome. Evidence for differential control of cardiovascular variables by glucocorticoids. 149
Analysis of BclI, N363S and ER22/23EK polymorphism of the glucocorticoid receptor gene in a large series of patients with adrenal incidentaloma 149
18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes 145
Acute administration of melatonin at two opposite circadian stages does not change responses to gonadotropin releasing hormone, thyrotropin releasing hormone and ACTH in healthy adult males. 142
Laboratory differentiation of Cushing's syndrome 141
May an adrenal incidentaloma change its nature? 137
Adrenal incidentaloma, a five year experience. 134
[Subclinical Cushing's syndrome in adrenal incidentalomas] 134
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients 132
Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood 132
Insights on the natural history of adrenal incidentalomas 130
Adjunctive treatment of adrenocortical carcinoma 129
Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis 128
CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma 122
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. 121
Evaluation of midnight salivary cortisol as a predictor factor for common carotid arteries intima media thickness in patients with clinically inapparent adrenal adenomas 121
Adrenal incidentalomas and subclinical Cushing's syndrome: is there evidence for glucocorticoid-induced osteoporosis? 116
Biochemical stress evaluation after medial parapatellar and subvastus approach in total knee replacement. 116
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study 113
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells 112
Adrenocortical Carcinoma with Hypercortisolism. 111
Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. 110
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment 110
Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study 109
[Drugs and andrological side-effects] 107
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study 106
Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. 105
Efficacia del reintervento chirurgico in pazienti con carcinoma del cortico-surrene recidivo 104
Evaluation of cardiovascular risk factors in patients with incidentally discovered adrenal adenoma during a follow-up longer than five years 104
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. 104
Totale 44.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.811
article - articoli 0
book - libri 0
conference - conferenze 8.572
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.383
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.125 0 0 511 675 520 838 715 652 760 573 467 414
2020/20216.890 520 435 579 427 592 512 635 551 580 689 551 819
2021/20227.460 477 516 525 690 598 439 613 605 456 550 1.022 969
2022/202310.885 821 778 483 845 723 1.473 854 825 1.306 955 933 889
2023/20249.944 1.128 1.033 812 834 843 851 769 788 267 747 813 1.059
2024/20253.198 1.286 1.435 477 0 0 0 0 0 0 0 0 0
Totale 56.060